| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/21/2009 | US7521071 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| 04/21/2009 | CA2434964C Carrier with solid fibrinogen and solid thrombin |
| 04/21/2009 | CA2362003C Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/21/2009 | CA2356263C Aminopyrazole derivatives |
| 04/21/2009 | CA2228038C 2(1h)-quinolone derivatives, their preparation and their use in therapy |
| 04/16/2009 | WO2009049318A2 Freeze-dried plasma formats for the trauma care field |
| 04/16/2009 | WO2009048849A1 Sterilised dialysis solutions containing pyrophosphates |
| 04/16/2009 | WO2009048067A1 Genetically engineered blood coagulation factor x having no sugar chain, and method for production thereof |
| 04/16/2009 | WO2009046632A1 Pharmaceutical composition containing angiotensin ii receptor blocker and b family vitamins and use thereof |
| 04/16/2009 | WO2009046631A1 Pharmaceutical composition containing angiotensin converting enzyme inhibitor and b family vitamins and use thereof |
| 04/16/2009 | WO2009046483A1 Therapeutic protocol for the treatment or prevention of thrombocytopenia |
| 04/16/2009 | WO2009007112A3 Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction |
| 04/16/2009 | WO2008040002A9 Methods, compositions and articles of manufacture for hif modulating compounds |
| 04/16/2009 | WO2007025049A3 Aptamers that bind thrombin with high affinity |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | US20090099241 Pharmaceutical composition containing antihypertensive agents |
| 04/16/2009 | US20090099223 Methods of treating hormone-related conditions using thio-oxindole derivatives |
| 04/16/2009 | US20090099145 Process for Producing a Single-phase Pharmaceutical Preparation for Limiting/Reducing the Risk of Deep Venous Thrombosis in Association with Oral Contraception |
| 04/16/2009 | US20090099139 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 04/16/2009 | US20090099100 Compositions and methods for treating amyloidosis |
| 04/16/2009 | US20090099073 Albumin Fusion Proteins |
| 04/16/2009 | US20090098215 Dialysis solutions containing pyrophosphates |
| 04/16/2009 | US20090098119 Antidotes for factor xa inhibitors and methods of using the same |
| 04/16/2009 | US20090098112 Novel antibodies |
| 04/16/2009 | CA2701763A1 Dialysis solutions containing pyrophosphates |
| 04/15/2009 | EP2048230A1 Cell death inducer |
| 04/15/2009 | EP2048229A1 Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| 04/15/2009 | EP2048228A2 Human liver progenitors |
| 04/15/2009 | EP2048150A1 Benzyl phenyl glucopyranoside derivative |
| 04/15/2009 | EP2047854A1 Pharmaceutical formulations containing ferrous bisglycinate chelate in combination with sweeteners (acesulfam K, sucralose, sorbitol) for improved palatability |
| 04/15/2009 | EP2047851A1 Drug formulation containing fibrate medicament and process for producing the same |
| 04/15/2009 | EP2046804A1 Synthesis of diethyl{ i5" (3 -fluorophenyl) -pyridine-2-yl] methyl} phosphonate used in the synthesis of himbacine analogs |
| 04/15/2009 | EP2046767A2 Process for preparing diaminophenothiazinium compounds |
| 04/15/2009 | EP2046748A1 Phenylpentadienoyl derivatives and their use as par 1 antagonists |
| 04/15/2009 | EP2046372A2 Factor viia analogues with increased activity for treating thrombocytopenia |
| 04/15/2009 | EP2046371A2 Factor viia analogues with increased activity for treating thrombocytopenia |
| 04/15/2009 | EP2046349A1 Treatment of excessive neovascularization |
| 04/15/2009 | EP1469891B1 Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| 04/15/2009 | EP1458408B1 Liquid composition of factor vii polypeptides |
| 04/15/2009 | EP1390490B1 Muscle-specific expression vectors |
| 04/15/2009 | EP1363635B1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 04/15/2009 | EP1311532B1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 04/15/2009 | EP1257295B1 Factor vii or viia-like molecules |
| 04/15/2009 | EP1203007B1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) and its receptor c-met |
| 04/15/2009 | EP1154999B1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity |
| 04/15/2009 | CN101407801A Preparation of earthworm fibrinolytic enzyme from Pheretima guillelmi Michaelsen and lyophilized powder preparation for injection prepared thereby |
| 04/15/2009 | CN101407743A Method for extracting and separating curcuma oil |
| 04/15/2009 | CN101407543A Labelled glutamine and lysine analogues |
| 04/15/2009 | CN101406662A Antioncotic medicinal powder |
| 04/15/2009 | CN101406656A Medicament for treating hepatic cirrhosis with hypoproteinemia after hepatitis |
| 04/15/2009 | CN101406621A Medicinal liquor for treating sequelae of cerebral thrombus |
| 04/15/2009 | CN101406603A Chinese herbal compound for treating gynaecologic metrorrhagia disease |
| 04/15/2009 | CN101406539A Medicament for treating thrombocytopenia after chemotherapy |
| 04/15/2009 | CN101406491A Oil-in-water Cordyceps sinensis emulsion and preparation technique |
| 04/15/2009 | CN101406485A Method for producing decoction for quickly relieving bowels |
| 04/15/2009 | CN101406290A Three-root tea |
| 04/15/2009 | CN100478636C Mounting arrangement for auxiliary burner or lance |
| 04/15/2009 | CN100477997C Hydrophobic formulation containing total notoginseng glycosides and phospholipid and preparation method thereof |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517974 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders |
| 04/14/2009 | US7517965 Non-neutralizing anti-aPC antibodies |
| 04/14/2009 | US7517909 Using 3-amino-5-methyl-octanoic acid for therapy of psychiatric, pain and other disorders |
| 04/14/2009 | US7517896 e.g. methyl 4-{[(5-ethoxy-5-oxopentyl)(2-methoxyphenethyl)amino]methyl}benzoate; stimulant of guanylate cyclase; catalyse the biosynthesis of cGMP from guanosine triphosphate (GTP); cardiovascular disorders; liver fibrosis |
| 04/14/2009 | US7517879 Pyrrolidine derivatives as factor Xa inhibitors |
| 04/14/2009 | US7517669 Increasing the intracellular amount of at least one ferritin-H or a derivative to an effective level for suppressing disease caused or enhanced by effects of intracellular iron mismanagement |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | US7517646 Provides functional molecule having an affinity and specificity to a target comparable to the affinity and specificity of an antibody against an antigen; modified oligonucleotide sequence |
| 04/14/2009 | CA2412213C A method for treating septic shock |
| 04/14/2009 | CA2387532C Suppressor of anemia and appetite suppressor |
| 04/14/2009 | CA2307175C Modified vitamin k-dependent polypeptides |
| 04/14/2009 | CA2130900C Therapeutic domains of von willebrand factor |
| 04/09/2009 | WO2009045412A2 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
| 04/09/2009 | WO2009045145A1 Novel compounds for the treatment or alleviation of edema, and methods for their use |
| 04/09/2009 | WO2009045123A1 Medicinal agent exhibiting hemopoiesis-stimulating and hepatoprotective actions |
| 04/09/2009 | WO2009044919A1 Stable bicarbonate ion-containing drug solution |
| 04/09/2009 | WO2009044765A1 Novel chondroitin sulfate having decreased molecular weight and use thereof |
| 04/09/2009 | WO2009043355A2 SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH |
| 04/09/2009 | WO2009043106A1 Inorganic selenium and angiogenesis |
| 04/09/2009 | WO2009043093A1 Hif inhibition |
| 04/09/2009 | WO2009025782A3 Hemostatic agent composition and method of delivery |
| 04/09/2009 | WO2008138943A3 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 04/09/2009 | WO2008082669A3 Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
| 04/09/2009 | WO2008082613A3 Factor ix moiety-polymer conjugates having a releasable linkage |
| 04/09/2009 | US20090093520 Plasma carboxypeptidase b inhibitors |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093419 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 04/09/2009 | US20090093410 Methods for Local Treatment with Factor VII |
| 04/09/2009 | US20090093402 Albumin Fusion Proteins |
| 04/09/2009 | US20090092693 Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092607 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092602 Use of anti-tissue factor antibodies for treating thromboses |
| 04/09/2009 | US20090092589 Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains |
| 04/09/2009 | US20090092546 Carrier molecules |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | CA2738070A1 Novel compounds for the treatment or alleviation of edema, and methods for their use |
| 04/09/2009 | CA2706254A1 Novel chondroitin sulfate having decreased molecular weight and use thereof |
| 04/09/2009 | CA2701555A1 Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on .alpha.-adrenergic and/or .beta.-adrenergic receptors of the sympathetic nervous system, related to improved clot strength |
| 04/09/2009 | CA2701249A1 Stable bicarbonate ion-containing drug solution |